Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Nutr Cancer ; 53(2): 208-19, 2005.
Article in English | MEDLINE | ID: mdl-16573382

ABSTRACT

A controlled balance among cell proliferation, differentiation, and apoptosis is required for the maintenance of gastrointestinal mucosa; these processes are influenced by luminal components, such as butyrate and bile acids. Using butyrate-sensitive (BCS-TC2) and butyrate-resistant (BCS-TC2.BR2) human colon carcinoma cells, we wanted to establish whether colon carcinoma cells that acquire resistance to butyrate-induced apoptosis are also resistant to the cytotoxic effect of certain bile acids, contributing, in this way, to the progression of colon carcinogenesis. The effect of bile acids on BCS-TC2 cell viability is dose and time dependent and highly stereospecific. Quantification of the relative percentage of apoptotic cells and caspase-3 activity reveals that deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA) induce apoptosis in BCS-TC2 cells. BCS-TC2.BR2 cells are consistently less sensitive to their cytotoxic effects, requiring concentrations to induce 50% inhibition (IC50) in cell viability of 740 microM and >1 mM for CDCA and DCA, respectively, compared with IC50 values of 310 and 540 microM for BCS-TC2 cells. DCA-treated BCS-TC2.BR2 cells show few apoptotic signs and no caspase-3 activation. On the other hand, CDCA-treated BCS-TC2.BR2 cells show caspase-3 activation and apoptotic features, although to a lower extent than BCS-TC2 cells. Our results, in an in vitro model system, point out that acquisition of butyrate resistance is accompanied by a partial resistance to the cytotoxic effects of bile acids, which may enhance the survival of tumorigenic cells.


Subject(s)
Adenocarcinoma/drug therapy , Bile Acids and Salts/pharmacology , Butyrates/pharmacology , Colonic Neoplasms/drug therapy , Adenocarcinoma/pathology , Apoptosis/drug effects , Caspase 3 , Caspases/metabolism , Cell Differentiation/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Colonic Neoplasms/pathology , Dose-Response Relationship, Drug , Drug Resistance, Neoplasm , Humans , Inhibitory Concentration 50 , Time Factors
2.
J Cell Sci ; 117(Pt 9): 1847-57, 2004 Apr 01.
Article in English | MEDLINE | ID: mdl-15075244

ABSTRACT

Association of matrix metalloprotease 9 (MMP9) to the cell membrane is considered important in tumor growth and angiogenesis. To dissect this regulatory mechanism, we generated raft and non-raft MMP9 chimeras to force membrane expression in the MCF-7 human breast carcinoma cell line. MMP9 targeting to non-raft cell surface domains rendered a constitutive active membrane MMP9 form, suggesting a contribution by the lipid environment in MMP activation. We generated human breast cancer xenograft models using MCF-7 cells overexpressing secreted and membrane-anchored MMP9. The non-raft MMP9 chimera was constitutively active at the cell membrane in xenografts, but this activation did not correlate with an increase in MMP9-induced angiogenesis. Capillary number and vessel perimeter were specifically increased only in tumors overexpressing wild-type MMP9 (the secreted form); this increase was inhibited when tumors were induced in doxycycline-treated mice. Xenografts from tumor cells overexpressing wild-type MMP9 showed increased vascular endothelial growth factor (VEGF)/VEGFR2 receptor association, which was also dependent on MMP9 activity. These observations indicate that membrane location can influence MMP9 activity in vitro and in vivo, and confirm the relevance of stromal-associated, but not tumor-bound MMP9 in mediating tumor-induced angiogenesis.


Subject(s)
Breast Neoplasms/enzymology , Breast Neoplasms/pathology , Cell Membrane/enzymology , Matrix Metalloproteinase 9/metabolism , Neovascularization, Pathologic/enzymology , Phenylalanine/analogs & derivatives , Cell Line, Tumor , Dipeptides/pharmacology , Doxycycline/pharmacology , Enzyme Activation/drug effects , Humans , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase Inhibitors , Membrane Microdomains/enzymology , Membrane Proteins/genetics , Membrane Proteins/metabolism , Phenylalanine/pharmacology , Protein Binding , Protein Transport , Receptors, LDL/genetics , Receptors, LDL/metabolism , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Thiophenes/pharmacology , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-2/metabolism , Xenograft Model Antitumor Assays
3.
Blood ; 101(1): 38-44, 2003 Jan 01.
Article in English | MEDLINE | ID: mdl-12393730

ABSTRACT

Homing of blood-borne lymphocytes to peripheral lymph nodes (PLNs) is a multistep process dependent on the sequential engagement of L-selectin, which mediates lymphocyte rolling along the luminal surface of high endothelial venules (HEVs), followed by activation of lymphocyte integrins and transmigration through HEVs. Within lymphoid tissue, B and T lymphocytes then migrate toward specific microenvironments such as B-cell follicles and the paracortex, respectively. The lymphocyte-expressed chemokine receptor CCR7 is playing an important role during this process, as its HEV-presented ligands CCL19 and CCL21 can trigger rapid integrin activation under flow in addition to inducing a chemotactic response, which may participate in transmigration and/or interstitial migration. Here, we report that Tyrphostin (Tyr) AG490, a pharmacological inhibitor of Janus family tyrosine kinases (Jaks), blocked the chemotactic response of primary mouse lymphocytes to CCL19 and CCL21 in a dose-dependent manner. Furthermore, Tyr AG490 inhibited rapid CCL21-mediated up-regulation of alpha4 and beta2 integrin adhesiveness in static adhesion assays and under physiological flow, whereas adhesion induced by phorbol myristate acetate remained unaltered. Using intravital microscopy of subiliac PLNs in mice, we found that adoptively transferred Tyr AG490-treated lymphocytes adhered significantly less in HEVs compared with control cells, although L-selectin-mediated rolling was similar in both samples. Finally, we observed rapid Jak2 phosphorylation in CCL21-stimulated primary mouse lymphocytes. Thus, our study suggests a role for Jak tyrosine kinases during CCR7-mediated lymphocyte recirculation.


Subject(s)
Chemotaxis, Leukocyte , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins , Receptors, Chemokine/physiology , Animals , Chemokine CCL19 , Chemokine CCL21 , Chemokine CXCL12 , Chemokines, CC/metabolism , Chemokines, CXC , Chemotaxis, Leukocyte/drug effects , Integrins/drug effects , Janus Kinase 2 , Lymph Nodes/blood supply , Lymph Nodes/cytology , Mice , Mice, Inbred BALB C , Microcirculation , Phosphorylation , Protein-Tyrosine Kinases/antagonists & inhibitors , Receptors, CCR7 , Receptors, Chemokine/metabolism , Receptors, Lymphocyte Homing , Signal Transduction , Tyrphostins/pharmacology
4.
FASEB J ; 16(8): 833-41, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12039865

ABSTRACT

Tissue remodeling during embryonic development and in the adult organism relies on a subtle balance between cell growth and apoptosis. As angiogenesis involves restructuring of preexisting endothelium, we examined the role of apoptosis in new vessel formation. We show that apoptosis occurs before capillary formation but not after vessels have assembled. Using the human umbilical vein endothelial cell (HUVEC) in vitro Matrigel angiogenesis model, we show that vascular-like structure formation requires apoptotic cell death through activation of a caspase-dependent mechanism and mitochondrial cytochrome c release. Vascular-like structure formation was further blocked by caspase inhibitors such as z-VAD or Ac-DEVD-CHO, using HUVEC and human lung microvascular endothelial cells. Overexpression of anti-apoptotic human Bcl-2 or baculovirus p35 genes in HUVEC altered endothelial cell rearrangement during in vitro angiogenesis, causing impaired vessel-like structure formation. Caspase inhibitors blocked VEGF- or bFGF-induced HUVEC angiogenesis on 2- or 3-D collagen gels, respectively, confirming that apoptosis was not the result of nonspecific cell death after seeding on the matrix. In an in vivo angiogenesis assay, caspase inhibitors blocked VEGF-dependent vascular formation at the alignment step, as demonstrated histologically. This evidence indicates that endothelial cell apoptosis may be relevant for precise vascular tissue rearrangement in in vitro and in vivo angiogenesis.


Subject(s)
Apoptosis/physiology , Endothelium, Vascular/physiology , Neovascularization, Physiologic/physiology , Amino Acid Chloromethyl Ketones/pharmacology , Animals , Blood Vessels/drug effects , Blood Vessels/physiology , Caspase 3 , Caspase Inhibitors , Caspases/metabolism , Cells, Cultured , Collagen , Cysteine Proteinase Inhibitors/pharmacology , Cytochrome c Group/metabolism , Drug Combinations , Endothelial Growth Factors/pharmacology , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Enzyme Activation , Female , Humans , Infant, Newborn , Jurkat Cells , Laminin , Lymphokines/pharmacology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mitochondria/metabolism , Neovascularization, Physiologic/drug effects , Oligopeptides/pharmacology , Proteoglycans , Rats , Time Factors , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...